GAMMA Investing LLC Grows Stock Position in Insulet Co. (NASDAQ:PODD)

GAMMA Investing LLC raised its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 27,298.6% during the first quarter, according to its most recent filing with the SEC. The firm owned 664,141 shares of the medical instruments supplier's stock after purchasing an additional 661,717 shares during the period. GAMMA Investing LLC owned 0.95% of Insulet worth $1,744,100,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in PODD. SBI Securities Co. Ltd. bought a new stake in shares of Insulet in the 4th quarter valued at about $36,000. Itau Unibanco Holding S.A. bought a new stake in shares of Insulet in the 4th quarter valued at about $42,000. SRS Capital Advisors Inc. boosted its holdings in shares of Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after buying an additional 56 shares in the last quarter. Assetmark Inc. boosted its holdings in shares of Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after buying an additional 246 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of Insulet by 117.3% in the 4th quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock valued at $72,000 after buying an additional 149 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on PODD shares. Wells Fargo & Company set a $322.00 price target on shares of Insulet in a report on Monday, April 28th. Oppenheimer raised their price target on shares of Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Wolfe Research upgraded shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target on the stock in a report on Tuesday, May 13th. Citigroup reiterated a "buy" rating and issued a $380.00 target price (up from $320.00) on shares of Insulet in a research note on Thursday, May 22nd. Finally, Sanford C. Bernstein reiterated an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Three investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $318.41.

Insulet Stock Performance

Insulet stock traded down $4.14 during midday trading on Tuesday, hitting $320.86. 322,397 shares of the company were exchanged, compared to its average volume of 786,868. The firm has a market capitalization of $22.58 billion, a PE ratio of 55.42, a price-to-earnings-growth ratio of 3.62 and a beta of 1.26. Insulet Co. has a fifty-two week low of $173.00 and a fifty-two week high of $329.33. The business has a fifty day simple moving average of $277.81 and a two-hundred day simple moving average of $272.24. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping the consensus estimate of $0.81 by $0.21. The firm had revenue of $569.00 million for the quarter, compared to analyst estimates of $543.20 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. Insulet's revenue for the quarter was up 28.8% compared to the same quarter last year. During the same period last year, the company earned $0.73 earnings per share. On average, sell-side analysts forecast that Insulet Co. will post 3.92 earnings per share for the current year.

Insider Buying and Selling

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the transaction, the senior vice president now owns 23,180 shares in the company, valued at approximately $7,382,134.60. This represents a 18.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now owns 3,231 shares in the company, valued at $888,525. This represents a 36.10% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by corporate insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.